This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 33.33% and 3.87%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 41.18% and 4.23%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 46.43% and 7.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
by Zacks Equity Research
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
by Zacks Equity Research
Spruce Biosciences, Inc. (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Spruce Biosciences, Inc. (SPRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
5 Beaten-Down Biotech Bets to Bounce Back in 2022
by Indrajit Bandyopadhyay
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Spruce Biosciences, Inc. (SPRB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Why Earnings Season Could Be Great for Spruce Biosciences (SPRB)
by Aditi Saraogi
Spruce Biosciences is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.